Hypothesis

Enhanced bioavailability from quercetin phytosome formulations pushes plasma concentrations into a range where quercetin acts as a general cytotoxin rather than a selective senolytic, abolishing the therapeutic window that underlies its senolytic activity.

Rationale

• Rat pharmacokinetics show quercetin aglycone reaches Cmax ≈ 25 µM, while isoquercitrin peaks at ≈1.2 µM [1].
• In vitro, free quercetin at 6 µM kills senescent and non‑senescent endothelial cells non‑selectively [3]; quercetin‑3‑glucoside at 100 µM shows no senolytic effect [3].
• Phytosome formulations reportedly increase bioavailability ~7‑fold relative to standard quercetin [2], which could readily shift Cmax from the low‑micromolar range (where selectivity might exist) into the ≥6 µM range where cytotoxicity becomes indiscriminate.
• The seed idea suggests that interventions mimicking scarcity (e.g., mTOR inhibition, caloric restriction) trigger conserved stress‑response programs. If quercetin’s senolytic action depends on a mild stress signal that selectively flags damaged cells, overshooting that signal with phytosome‑driven exposure may convert a nuanced alarm into a blunt, lethal shock, erasing selectivity.

Testable Predictions

1. Plasma concentration‑time curves for phytosome‑delivered quercetin will surpass 6 µM at Cmax in humans.
2. Ex vivo assays using matched senescent and non‑senescent human cells will show a declining senescent‑to‑non‑senescent killing ratio as quercetin concentration rises above ~6 µM.
3. Isoquercetin, with lower exposure, will maintain a higher selectivity ratio despite lower overall AUC.

Experimental Design

• Conduct a crossover pharmacokinetic study in healthy volunteers receiving equimolar doses of standard quercetin, quercetin phytosome, and isoquercetin (query: use doses that yield comparable molar intake).
• Serial blood draws to construct AUC and Cmax profiles; quantify free quercetin via LC‑MS/MS.
• At each timepoint, isolate plasma and add it to cultured human senescent and non‑senescent fibroblasts (or endothelial cells) in vitro.
• Measure viability after 24 h to derive a selectivity index (viability of non‑senescent ÷ viability of senescent).
• Plot selectivity index against concurrent plasma quercetin concentration.

Potential Outcomes

• If selectivity index declines sharply once plasma quercetin exceeds ~6 µM for phytosome (but remains higher for isoquercetin), the hypothesis is supported: phytosome’s increased exposure sacrifices selectivity.
• If selectivity remains high across the entire concentration range for all formulations, the hypothesis is falsified, suggesting that quercetin’s senolytic effect operates via a mechanism not limited by cytotoxic thresholds.
• This work would directly link pharmacokinetic exposure to pharmacodynamic selectivity, informing dosing strategies that preserve the therapeutic window rather than merely maximizing AUC.